Statement of Deviation & Variation
Statement Of Deviation & Variation
View original source (BSE India)Transgene Biotek Limited on 6ix
Earlier from Transgene Biotek
- Compliance-57 (5): intimation after the end of quarter
- Compliance-57 (4): Prior intimation to the beginning of the quarter
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate: Annexure A
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Transgene Biotek Limited. Press Release Dec 30 2025
Later from Transgene Biotek
- Declaration Under Clause 36 Of Listing Agreement With BSEPROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBI
- Transgene Biotek Limited. Press Release Feb 03 2026
- Board Meeting Outcome for Outcome Of Board Meeting
- Dear Sir/Madam,This Has Reference To Our Letter Dated January 28 2026.1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company, For The Quarter Ended 31.12.2025 In Accordance With The Indian A
- Transgene Biotek Limited. Press Release Feb 13 2026
Follow Transgene Biotek into a list and get an email when it puts out news.
Follow Transgene Biotek